+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for PNH Market - Global Forecast 2026-2032- Product Image
Drugs for PNH Market - Global Forecast 2026-2032- Product Image
New

Drugs for PNH Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 196 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117908
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drugs for PNH Market grew from USD 1.92 billion in 2025 to USD 2.06 billion in 2026. It is expected to continue growing at a CAGR of 9.02%, reaching USD 3.51 billion by 2032.

An authoritative overview that frames paroxysmal nocturnal hemoglobinuria therapeutic evolution, clinical priorities, and implications for stakeholders across care pathways

Paroxysmal nocturnal hemoglobinuria (PNH) represents a distinct, life-altering hematologic condition that has reshaped therapeutic priorities for clinicians, payers, and developers. Patients experience hemolysis, thrombosis risk, and chronic morbidity that demand sustained clinical attention and targeted pharmacologic strategies. Over recent years, the therapeutic landscape has migrated from broad supportive care toward mechanism-based biologic therapies that selectively inhibit complement pathway components, delivering meaningful clinical benefit and altering long-term management paradigms.

The introduction of terminal complement inhibitors revolutionized acute disease control, followed by the emergence of proximal complement inhibitors that expand options for patients with residual hemolysis or incomplete response. These pharmacologic innovations have shifted treatment objectives from purely symptom mitigation to improved quality of life and reduced transfusion dependence. Consequently, stakeholders across clinical, commercial, and regulatory domains are recalibrating priorities to address administration preferences, safety profiles, and real-world effectiveness while also adapting care delivery models to support chronic administration and monitoring.

How breakthroughs in complement biology, administration formats, and care delivery are reshaping clinical decision-making and commercial strategies in PNH

The PNH treatment environment is undergoing transformative shifts driven by innovation in complement biology, evolving administration formats, and changing expectations for patient-centric care. Proximal complement inhibition has introduced a fundamentally different mechanism of action compared with established terminal inhibitors, prompting clinicians to reassess sequencing, combination potential, and long-term safety monitoring. Simultaneously, advances in formulation science have enabled subcutaneous delivery, which reduces infusion burden and unlocks broader settings of care, including home administration and decentralized specialty services.

These scientific and delivery innovations are catalyzing commercial and operational changes. Payers and providers are increasingly prioritizing therapies that demonstrate tangible improvements in daily functioning and reduced healthcare utilization. Manufacturers are responding by optimizing patient support programs, strengthening cold‑chain logistics for biologics, and pursuing label expansions supported by head-to-head and real-world evidence. As a result, the aggregate effect is a healthcare ecosystem that is more receptive to personalized treatment algorithms and value-based contracting models that align clinical outcomes with reimbursement frameworks.

Assessing how 2025 tariff shifts interact with global pharmaceutical supply chains, procurement strategies, and access dynamics for paroxysmal nocturnal hemoglobinuria therapies

Policy and trade developments in 2025 have introduced an added layer of complexity for stakeholders reliant on global pharmaceutical supply chains and cross-border procurement. Cumulative tariff adjustments can increase the landed cost of imported active pharmaceutical ingredients, biologic components, and finished drug products, particularly for therapies manufactured or formulated in foreign facilities. In response, manufacturers, distributors, and healthcare institutions must evaluate sourcing strategies and consider nearshoring or regional supply hub investments to maintain uninterrupted patient access and to mitigate cost volatility.

Beyond direct cost implications, tariffs interact with contract negotiations and reimbursement dynamics. Higher procurement costs can pressure health systems and payers to demand price concessions, seek formulary restrictions, or pivot toward therapies with lower overall treatment burden when clinically appropriate. Moreover, tariffs can slow the adoption curve for newly launched therapies if distribution agreements and contracting pathways require renegotiation. To preserve continuity of care, stakeholders should integrate tariff exposure assessments into commercial modeling, risk-share negotiations, and supply chain contingency planning.

Detailed segmentation reveals how drug class, administration route, distribution channels, end users, therapy lines, and age cohorts collectively shape clinical and commercial pathways

Segmentation of the PNH therapeutic landscape illuminates heterogeneous clinical and commercial realities that influence development and access strategies. By drug class, the market is composed of proximal complement inhibitors, exemplified by agents such as pegcetacoplan, and terminal complement inhibitors, represented by eculizumab and ravulizumab, each offering distinct mechanisms and clinical trade-offs that affect patient selection and long-term monitoring. These distinctions cascade into route of administration considerations, where intravenous options such as eculizumab and ravulizumab require infusion infrastructure and periodic monitoring, while subcutaneous formulations like pegcetacoplan enable more flexible dosing schedules and broadened settings of care.

Distribution channels further differentiate access pathways: home infusion services, hospital pharmacy systems, and specialty pharmacy networks each present unique logistical, reimbursement, and patient-support implications that influence adherence and total cost of care. End-user dynamics play a complementary role, with clinics, home care programs, and hospitals varying in their capacity to manage complex biologics and handle adverse-event workflows. Line-of-therapy segmentation highlights decision points between first-line selection and subsequent-line strategies, where clinical history, prior response, and safety profiles guide therapeutic transitions. Age group considerations split adult and pediatric populations, necessitating tailored dosing strategies, caregiver engagement, and long-term safety surveillance that shape clinical trial design and post-marketing evidence generation.

Regional nuances in access pathways, regulatory priorities, and care delivery across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate strategic approaches

Regional dynamics exert a decisive influence on how PNH therapies are developed, accessed, and administered across diverse healthcare systems. In the Americas, payer structures, reimbursement processes, and established specialty infrastructure facilitate rapid adoption of clinically differentiated biologics, while patient advocacy and specialty provider networks drive demand for therapies that reduce transfusion dependence and improve quality of life. These regional characteristics also incentivize manufacturers to invest in comprehensive patient support services and hub programs to navigate complex prior authorization and reimbursement pathways.

Europe, the Middle East & Africa present a mosaic of regulatory approaches and pricing frameworks that shape market entry sequencing and evidence-generation priorities. In some jurisdictions centralized health technology assessment and national procurement influence launch strategies, compelling companies to pursue robust comparative and health‑economic data early in development. Meanwhile, Asia‑Pacific markets are marked by heterogeneous regulatory maturity and growing investment in local biologics manufacturing. Several countries within the region are expanding specialty care capacity and exploring accelerated access pathways for high‑impact therapies, which opens opportunities for targeted partnerships and regional supply models that reduce lead times and enhance affordability.

How leading developers and strategic partners are aligning scientific differentiation, manufacturing resilience, and patient support to drive access and adoption

Key companies operating in the PNH ecosystem are advancing differentiated scientific approaches, distribution partnerships, and patient-support infrastructures to address the complex needs of this patient population. Established developers of terminal complement inhibition continue to optimize long‑acting formulations and refine post-marketing safety monitoring, while newer entrants focused on proximal complement inhibition are generating comparative data and real‑world evidence to position their therapies for specific patient subgroups. Across the competitive landscape, companies are investing in manufacturing scale, supply chain resilience, and digital patient engagement tools to improve adherence and reduce treatment burden.

Collaborations between manufacturers, contract manufacturers, specialty pharmacies, and clinical networks are increasingly common to ensure steady supply and synchronized patient care pathways. Strategic alliances that enable co‑development of diagnostic algorithms, biomarker-driven patient selection, and combined registry initiatives strengthen evidentiary support for therapy differentiation and payer negotiations. As the therapeutic field evolves, companies that balance robust clinical data generation with pragmatic delivery models and proactive payer engagement will be best positioned to translate scientific advantage into sustainable patient access.

Actionable strategic priorities for manufacturers, payers, and providers to fortify access, optimize value demonstration, and build resilient delivery models in PNH

Industry leaders should prioritize integrated strategies that align clinical differentiation with pragmatic delivery models to safeguard patient access and optimize long‑term outcomes. Manufacturers must embed supply chain stress‑testing and tariff exposure analyses into commercial planning, while simultaneously accelerating evidence generation that demonstrates comparative benefit and population-level value. In parallel, stakeholders should expand decentralized care models where clinically appropriate, leveraging subcutaneous administration and home-based services to reduce facility burden and enhance patient convenience.

Payers and providers ought to collaborate on innovative contracting approaches that reward demonstrated improvements in transfusion dependence, hospitalization rates, and patient-reported outcomes. Research and development teams should focus on head-to-head trials and real-world registry studies that clarify positioning across lines of therapy and age cohorts. Finally, cross-sector partnerships that align diagnostic strategies, adherence programs, and digital monitoring will be essential to convert mechanistic advantage into measurable clinical benefit and sustainable access pathways in diverse regional contexts.

A transparent, multidisciplinary methodology combining clinical evidence synthesis, expert engagement, and supply chain analysis to underpin robust strategic insights

This research approach combined rigorous synthesis of peer-reviewed literature, public regulatory filings, clinical trial registries, and validated expert interviews to assemble a comprehensive view of the PNH therapeutic landscape. Clinical evidence was contextualized by qualitative input from hematology specialists, infusion center administrators, and specialty pharmacy leaders to capture real-world operational constraints and evolving standards of care. Supply chain and policy analysis incorporated trade publications, tariff schedules, and logistics data to evaluate potential points of disruption and adaptation without relying on single-source commercial projections.

Analytic rigor was maintained through triangulation of data streams and scenario-based sensitivity assessment to surface resilient insights and practical recommendations. Wherever possible, evidence was cross-checked against multiple sources and interpreted with caution to avoid overextension beyond the available clinical and operational data. This methodology enables decision-makers to apply findings to strategic planning, product life-cycle management, and partnership development while recognizing inherent uncertainties in policy and market dynamics.

Synthesizing therapeutic innovation, delivery transformation, and policy pressures to chart a resilient pathway for clinical impact and sustained access in PNH

The evolution of PNH therapeutics illustrates how scientific innovation, delivery flexibility, and policy dynamics converge to reshape patient care and commercial strategy. Emerging proximal inhibitors and subcutaneous formulations expand therapeutic choice and create opportunities to shift care into less resource-intensive settings, while longstanding terminal inhibitors maintain a vital role for many patients. Concurrently, trade and procurement developments underscore the need for supply chain resilience and collaborative payer-provider engagement to preserve access when external pressures increase operational costs.

Taken together, stakeholders that proactively align clinical evidence generation with pragmatic delivery models and proactive payer strategies will be best positioned to deliver improved outcomes for patients. Continued investment in comparative studies, real-world evidence, and cross‑regional manufacturing strategies will be central to navigating persistent uncertainties and to ensuring that therapeutic innovations translate into broad, equitable access for people living with PNH.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Comparative real-world efficacy and safety outcomes of ravulizumab versus eculizumab in PNH patients over extended dosing intervals
5.2. Market penetration and pricing dynamics of emerging oral complement inhibitors in the global PNH landscape
5.3. Impact of biosimilar eculizumab approvals on treatment affordability and payer reimbursement policies for PNH
5.4. Development and clinical trial progress of proximal complement inhibitors targeting C3 and factor D in PNH patients
5.5. Patient-reported quality of life assessments and treatment satisfaction trends across diverse PNH therapy regimens
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for PNH Market, by Drug Class
8.1. Introduction
8.2. Proximal Complement Inhibitors
8.2.1. Pegcetacoplan
8.3. Terminal Complement Inhibitors
8.3.1. Eculizumab
8.3.2. Ravulizumab
9. Drugs for PNH Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.2.1. Eculizumab
9.2.2. Ravulizumab
9.3. Subcutaneous
9.3.1. Pegcetacoplan
10. Drugs for PNH Market, by Distribution Channel
10.1. Introduction
10.2. Home Infusion
10.3. Hospital Pharmacy
10.4. Specialty Pharmacy
11. Drugs for PNH Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
12. Drugs for PNH Market, by Line Of Therapy
12.1. Introduction
12.2. First-Line
12.3. Subsequent-Line
13. Drugs for PNH Market, by Age Group
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Americas Drugs for PNH Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Drugs for PNH Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Drugs for PNH Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Alexion Pharmaceuticals, Inc.
17.3.2. Apellis Pharmaceuticals, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DRUGS FOR PNH MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DRUGS FOR PNH MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRUGS FOR PNH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR PNH MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR PNH MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DRUGS FOR PNH MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DRUGS FOR PNH MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. DRUGS FOR PNH MARKET: RESEARCHAI
FIGURE 28. DRUGS FOR PNH MARKET: RESEARCHSTATISTICS
FIGURE 29. DRUGS FOR PNH MARKET: RESEARCHCONTACTS
FIGURE 30. DRUGS FOR PNH MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DRUGS FOR PNH MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR PNH MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR PNH MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR PNH MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR PNH MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DRUGS FOR PNH MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DRUGS FOR PNH MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DRUGS FOR PNH MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DRUGS FOR PNH MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBSEQUENT-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBSEQUENT-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 113. CANADA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. CANADA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. CANADA DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. CANADA DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. CANADA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 118. CANADA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 119. CANADA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. CANADA DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 122. CANADA DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 123. CANADA DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 124. CANADA DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 125. CANADA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. CANADA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. CANADA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. CANADA DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. CANADA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 130. CANADA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 131. CANADA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 132. CANADA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 133. MEXICO DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 144. MEXICO DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 145. MEXICO DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. MEXICO DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. MEXICO DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. MEXICO DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. MEXICO DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. MEXICO DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 235. GERMANY DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 236. GERMANY DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 237. GERMANY DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. GERMANY DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. GERMANY DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. GERMANY DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. GERMANY DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 247. GERMANY DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. GERMANY DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. GERMANY DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. GERMANY DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. GERMANY DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 252. GERMANY DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 253. GERMANY DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 254. GERMANY DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 255. FRANCE DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. FRANCE DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. FRANCE DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. FRANCE DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. FRANCE DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 265. FRANCE DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 266. FRANCE DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 267. FRANCE DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. FRANCE DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. FRANCE DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. FRANCE DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. FRANCE DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 272. FRANCE DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 273. FRANCE DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 274. FRANCE DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 295. ITALY DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 296. ITALY DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 297. ITALY DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 298. ITALY DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 299. ITALY DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. ITALY DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. ITALY DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. ITALY DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. ITALY DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 304. ITALY DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 305. ITALY DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 306. ITALY DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 307. ITALY DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. ITALY DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. ITALY DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. ITALY DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. ITALY DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 312. ITALY DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 313. ITALY DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 314. ITALY DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 315. SPAIN DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 316. SPAIN DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 317. SPAIN DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 318. SPAIN DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 319. SPAIN DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 320. SPAIN DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 321. SPAIN DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 322. SPAIN DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 323. SPAIN DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 324. SPAIN DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 325. SPAIN DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 326. SPAIN DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 327. SPAIN DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 328. SPAIN DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 329. SPAIN DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 330. SPAIN DRUGS FOR PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 331. SPAIN DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 332. SPAIN DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 333. SPAIN DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 334. SPAIN DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 336. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 337. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 338. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 339. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 340. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 341. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 342. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 343. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 344. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 345. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 346. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 347. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 348. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 349. UNITED ARAB EMIRATES DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2024

Companies Mentioned

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ra Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Swedish Orphan Biovitrum AB
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages196
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.06 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.51 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Veopoz Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Veopoz Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Anti-amyloid Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-amyloid Drugs Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Gout Medications Market - Global Forecast 2026-2032 - Product Image

Gout Medications Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Vyvgart (Efgartigimod) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Vyvgart (Efgartigimod) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Pharmaceutical Market Size, Share & Trends Analysis Report by Molecule Type, Product, Type, Disease, Age Group, Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Pharmaceutical Market Size, Share & Trends Analysis Report by Molecule Type, Product, Type, Disease, Age Group, Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.